Our pipeline 2020

Focused Product

We are currently exploring and optimizing single bacterial strains to deliver best-in-class microbiome-based therapies in obesity as well as metabolic disorders, inflammation and neurology.

Our Live Biotherapeutics are dedicated to unlocking the therapeutic value of Christensenella, as well as other microbiome bacteria.

LNC01 Program 

LNC01 is a development project aiming at harnessing the potential of Christensenella minuta as a novel therapy to treating obesity and metabolic disorders. 

This program is built on first-in-class scientific publications that have identified christensenella as a cornerstone of healthy human intestinal microbiota.
The bacterial strain specifically selected for this program comes from LNC Therapeutics’ proprietary library.

LNC01 showed strong efficacy results in preclinical animal models and is expected to enter clinical development in 2020.  


Many inflammatory disorders have been associated with alterations of the gut microbiome. LNC Therapeutics therefore focusses on restoring the gut microbial symbiosis specifically altered in some inflammatory pathologies using carefully selected single strain bacteria. 

Our approach is supported by compelling epidemiological and clinical data that have demonstrated a strong link between the presence of keystone bacteria and reduced risks of developing inflammatory bowel disorders.

more +

General review of gut microbiome changes in IBD showing consistant association between CD and a loss of Christensenellacea
Pittayanon, R., Lau, J.T., Leontiadis, G.I., Tse, F., Yuan, Y., Surette, M., and Moayyedi, P. (2019). Differences in Gut Microbiota in Patients With vs Without Inflammatory Bowel Diseases: a Systematic Review. Gastroenterology 1–52.

Important paper showing that loss of Christensenella is predictive of CD flare.
Braun, T., Di Segni, A., BenShoshan, M., Neuman, S., Levhar, N., Bubis, M., Picard, O., Sosnovski, K., Efroni, G., Farage Barhom, S., et al. (2019). Individualized Dynamics in the Gut Microbiota Precede Crohnʼs Disease Flares. Am. J. Gastroenterol. 1–10.


Over the last 10 years, there has been increasing evidence that the gut microbiome was associated with neurological and behavioural disorders, which led to the so called “gut-brain axis” concept.

Multiple complex mechanisms of action are at play in this relationship, but although there is still a lot to discover, there is strong support for an action of the gut microbiome on neuroinflammation. LNC Therapeutics is therefore initiating research in this exciting area to harness the potential of carefully selected bacteria strains to treat behavioural diseases that are linked to gut dysbiosis.


more +

Pr. John Cryan, a neuropharmacologist and microbiome expert from the University College Cork, shares surprising facts and insights about how our thoughts and emotions are connected to our gut.

Discover John Cryan on TEDMED

Microbiome & us
Mar 12, 2020
LNC Therapeutics Announces Successful GMP Manufacturing of Xla1 for Phase 1 Clinical Trial | By finalizing the...
> more
Jan 13, 2020
We are looking for Clinical Project Manager | WHAT WE OFFER An exciting opportunity to dive in and begin your career...
> more
Press / Media
Nov 12, 2019
Biotechs investments disrupt Big Pharma business model The pharmaceutical industry is in a state of flux, with...
> more
Sep 6, 2019
Chaque semaine, Maddyness dresse le bilan des levées de fonds de la semaine qui vient de s’écouler. Cette semaine,...
> more
Dec 6, 2019
The term “microbiome” refers to the collection of microorganisms (or microbiota) – including bacteria, viruses and...
> more
Oct 28, 2019
Jillian L. Waters, Ruth E. Ley The Christensenellaceae, a recently described family in the phylum Firmicutes, is emerging...
> more
now on twitter
LNC Therapeutics

Do you have some extra #ReadingTime? Find out more about how this new study discovered tissue bacterial signatures… t.co/RHnupokNK1

LNC Therapeutics © 2020 - all rights reserved terms and conditions